[1]
|
A. K. Kumar, K. Mazumdar, N. K. Dutta, P. Karak, S. G. Dastidar and R. Ray, “Evaluation of Synergism between the Aminoglycoside Antibiotic Streptomycin and the Cardiovascular Agent Amlodipine,” Biological and Pharmaceutical Bulletin, Vol. 27, No. 7, 2004, pp. 1116-1120.
doi:10.1248/bpb.27.1116
|
[2]
|
D. A. Stopher, A. P. Beresford, P. V. Macrae and M. J. Humphrey, “The Metabolism and Pharmacokinetics of Amlopidine in Humans and Animals,” Journal of Cardiovascular Pharmacology, Vol. 12, Suppl. 7, 1988, pp. 55-59. doi:10.1097/00005344-198812007-00012
|
[3]
|
W. R. Byrne, S. L. Welkos, M. L. Pitt, K. J. Davis, R. P. Brueckner, J. W. Ezzell, G. O. Nelson, J. R. Vaccaro, L. C. Battersby and A. M. Friedlander, “Antibiotic Treatment of Experimental Pneumonic Plague in Mice,” Antimicrobial Agents and Chemotherapy, Vol. 42, No. 3, 1998, pp. 675-681.
|
[4]
|
S. Blot, P. Depuydt, K. Vandewoude and D. De Bacquer, “Measuring the Impact of Multidrug Resistance in Nosocomial Infection,” Current Opinion in Infectious Diseases, Vol. 20, No. 4, 2007, pp. 391-396.
doi:10.1097/QCO.0b013e32818be6f7
|
[5]
|
I. Chopra, C. Schofield, M. Everett, A. O’Neill, K. Miller, M. Wilcox, J. M. Frère, M. Dawson, L. Czaplewski, U. Urleb and P. Courvalin, “Treatment of Health-Care-Associated Infections Caused by Gram-Negative Bacteria: A Consensus Statement,” The Lancet Infectious Diseases, Vol. 8, No. 2, 2008, pp. 133-139.
doi:10.1016/S1473-3099(08)70018-5
|
[6]
|
M. E. Falagas and I. A. Bliziotis, “Pandrug-Resistant Pandrug-Resistant Gram-Negative Bacteria: The Dawn of the Post-Antibiotic Era?” International Journal of Antimicrobial Agents, Vol. 29, No. 6, 2007, pp. 630-636.
doi:10.1016/j.ijantimicag.2006.12.012
|
[7]
|
A. Davin-Regli, J. M. Bolla, C. E. James, J. P. Lavigne, J. Chevalier, E. Garnotel, A. Molitor and J.-M. Pagès, “Membrane Permeability and Regulation of Drug ‘Influx and Efflux’ in Enterobacterial Pathogens,” Current Drug Targets, Vol. 9, No. 9, 2008, pp. 750-759.
doi:10.2174/138945008785747824
|
[8]
|
M. Lipsitch and B. R. Levin, “The Population Dynamics of Antimicrobial Chemotherapy,” Antimicrobial Agents and Chemotherapy, Vol. 41, No. 2, 1997, pp. 363-373.
|
[9]
|
A. Handel, E. Margolis and B. R. Levin, “Exploring the Role of the Immune Response in Preventing Antibiotic Resistance,” Journal of Theoretical Biology, Vol. 256, No. 4, 2009, pp. 655-662. doi:10.1016/j.jtbi.2008.10.025
|
[10]
|
J. M. Pagès and L. Amaral, “Mechanisms of Drug Efflux and Strategies to Combat Them: Challenging the Efflux Pump of Gram-Negative Bacteria,” Biochimica et Biophysica Acta, Vol. 1794, No. 5, 2009, pp. 826-833.
|
[11]
|
K. I. Udekwu, N. Parrish, P. Ankomah, F. Baquero and B. R. Levin, “Functional Relationship between Bacterial Cell Density and the Efficacy of Antibiotics,” Journal of Antimicrobial Chemotherapy, Vol. 63, No. 4, 2009, pp. 745-757. doi:10.1093/jac/dkn554
|
[12]
|
J. J. Campion, P. J. McNamara and M. E. Evans, “Pharmacodynamic Modeling of Ciprofloxacin Resistance in Staphylococcus Aureus,” Antimicrobial Agents and Chemotherapy, Vol. 49, No. 1, 2005, pp. 209-219.
doi:10.1128/AAC.49.1.209-219.2005
|
[13]
|
P. Chung, P. J. McNamara, J. J. Campion and M. E. Evans, “Mechanism-Based Pharmacodynamic Models of Fluoroquinolone Resistance in Staphylococcus aureus,” Antimicrobial Agents and Chemotherapy, Vol. 50, No. 9, 2006, pp. 2957-2965. doi:10.1128/AAC.00736-05
|
[14]
|
J. E. Kristiansen, “Antimicrobial Activity of Non-Antibiotics,” ASM News, Vol. 57, 1991, p. 135.
|
[15]
|
J. E. Kristiansen, “Chlorpromazine Non-Antibiotics with Antimicrobial Activity-New Insight in Managing Resistance?” Current Opinion in Investigational Drugs, Vol. 2, 1993, pp. 587-591.
|
[16]
|
J. E. Kristiansen and L. Amaral, “The Potential Management of Resistant Infections with Non-Antibiotics,” Journal of Antimicrobial Chemotherapy, Vol. 40, No. 3, 1997, pp. 319-327. doi:10.1093/jac/40.3.319
|
[17]
|
J. E. Kristiansen, O. Hendricks, T. Delvin, T. S. Butterworth, L. Aagaard, J. B. Christensen, V. C. Flores and H. Keyzer, “Reversal of Resistance in Microorganisms by Help of Non-Antibiotic,” Journal of Antimicrobial Chemotherapy; Vol. 59, No. 6, 2007, pp. 1271-1279.
doi:10.1093/jac/dkm071
|
[18]
|
G. W. Kaatz, V. V. Moudgal, S. M. Seo and J. E. Kristiansen, “Phenothiazines and Thioxanthenes Inhibit Multidrug Efflux Pump Activity in Staphylococcus aureus,” Antimicrobial Agents and Chemotherapy, Vol. 47, No. 2, 2003, pp. 719-726. doi:10.1128/AAC.47.2.719-726.2003
|
[19]
|
O. Lomovskaya, M. S. Warren, A. Lee, J. Galazzo, R. Fronko, M. Lee, J. Blais, D. Cho, S. Chamberland, T. Renau, R. Leger, S. Hecker, W. Watkins, K. Hoshino, H. Ishida and V. J. Lee, “Identification and Characterization of Inhibitors of Multidrug Resistance Efflux Pumps in Pseudomonas aeruginosa: Novel Agents for Combination Therapy,” Antimicrobial Agents and Chemotherapy, Vol. 45, No. 1, 2001, pp. 105-116.
doi:10.1128/AAC.45.1.105-116.2001
|
[20]
|
H. Nikaido and H. I. Zgurskaya, “AcrAB and Related Multidrug Efflux Pumps of Escherichia coli,” Journal of Molecular Microbiology and Biotechnology, Vol. 3, No. 2, 2001, pp. 215-218.
|
[21]
|
F. Van Bambeke, Y. Glupczynski, P. Plésiat, J. C. Pechère and P. M. Tulkens, “Antibiotic Efflux Pumps in Prokaryotic Cells: Occurrence, Impact on Resistance and Strategies for the Future of Antimicrobial Therapy,” Journal of Antimicrobial Chemotherapy, Vol. 51, No. 5, 2003, pp. 1055-1065. doi:10.1093/jac/dkg224
|
[22]
|
W. J. Gooderham and R. E. Hancock, “Regulation of Virulence and Antibiotic Resistance by Two-Component Regulatory Systems in Pseudomonas aeruginosa,” FEMS Microbiology Reviews, Vol. 33, No. 2, 2009, pp. 279-294.
doi:10.1111/j.1574-6976.2008.00135.x
|
[23]
|
K. Nishino, E. Nikaido and A. Yamaguchi, “Regulation and Physiological Function of Multidrug Efflux Pumps in Escherichia coli and Salmonella,” Biochimica et Biophysica Acta, Vol. 1794, No. 5, 2009, pp. 834-843.
|
[24]
|
L. Sandegren and D. I. Andersson, “Bacterial Gene Amplification: Implications for the Evolution of Antibiotic Resistance,” Nature Reviews Microbiology, Vol. 7, No. 8, 2009, pp. 578-588. doi:10.1038/nrmicro2174
|
[25]
|
J. L. Martinez, A. Fajardo, L. Garmendia, A. Hernandez, J. F. Linares, L. Martínez-Solano and M. B. Sánchez, “A Global View of Antibiotic Resistance,” FEMS Microbiology Reviews, Vol. 33, No. 1, 2009, pp. 44-65.
doi:10.1111/j.1574-6976.2008.00142.x
|
[26]
|
M. Martins, S. G. Dastidar, S. Fanning, J. E. Kristiansen, J. Molnar, J. M. Pagès, Z. Schelz, G. Spengler, M. Viveiros and L. Amaral, “Potential Role of Non-Antibiotics (Helper Compounds) in the Treatment of Multidrug-Resistant Gram-Negative Infections: Mechanisms for Their Direct and Indirect Activities,” International Journal of Antimicrobial Agents, Vol. 31, No. 3, 2008, pp. 198-208. doi:10.1016/j.ijantimicag.2007.10.025
|
[27]
|
J. E. Kristiansen, O. Sebbesen, N. Frimodt-M?ller, T. Aaes-J?rgensen and E. F. Hvidberg, “Synergy between a Non-Neuroleptic Thioxanthene Stereo-Isomer and Penicillin in Vivo,” Acta Pathologica, Microbiologica et Immunologica Scandinavica, Vol. 96, No. 12, 1988, pp. 1079-1084. doi:10.1111/j.1699-0463.1988.tb00984.x
|
[28]
|
J. Molnár, I. Haszon, T. Bodrogi, E. Martonyi, and S. Turi, “Synergistic Effect of Promethazine with Gentamycin in Frequently Recurring Pyelonephrotis,” International Urology and Nephrology, Vol. 22, No. 5, 1990, pp. 405-411. doi:10.1007/BF02549770
|
[29]
|
J. M. Bolla, S. Alibert-Franco, J. Handzlik, J. Chevalier, A. Mahamoud, G. Boyer, K. Kiec-Kononowicz and J.-M. Pages, “Strategies for Bypassing the Membrane Barrier in Multidrug Resistant Gram-Negative Bacteria,” FEBS Letters, Vol. 585, No. 11, 2011, pp. 1682-1690.
doi:10.1016/j.febslet.2011.04.054
|